| GFACX | MRLTX | GFACX / MRLTX | |
| Total Expense Ratio | 1.35 | 1.00 | 135% |
| Annual Report Gross Expense Ratio | 1.35 | 1.11 | 122% |
| Fund Existence | 25 years | 17 years | - |
| Gain YTD | 1.530 | 2.170 | 71% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 2000 | 13% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 336B | 136M | 247,059% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | 4.83 | -4.50 | -107% |
| Returns for 3 years | 47.58 | 18.01 | 264% |
| Returns for 5 years | 10.69 | 14.44 | 74% |
| Returns for 10 years | 95.34 | 75.74 | 126% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MKGCX | 31.05 | 0.09 | +0.29% |
| BlackRock Advantage Global K | |||
| IBLLX | 35.18 | 0.03 | +0.09% |
| Transamerica Multi-Managed Balanced C | |||
| CMRAX | 10.22 | N/A | N/A |
| Calamos Merger Arbitrage A | |||
| FWOCX | 18.59 | N/A | N/A |
| Fidelity Advisor Women's Leadership C | |||
| JAGLX | 81.88 | -0.47 | -0.57% |
| Janus Henderson Global Life Sciences T | |||